# Tactiva Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tactiva-therapeutics

- Industry: Biotechnology
- Headquarters: Buffalo, US
- Website: www.tactivatherapeutics.com
- Total disclosed funding: $35M
- Latest round: Series A (Dec 3, 2018)
- Investors on record: 3

## About

Tactiva Therapeutics is dedicated to innovating cancer treatments through advanced immunotherapy techniques, specifically focusing on developing adoptive cell therapies that target solid tumors.Founded in 2016 and headquartered in Buffalo, US, Tactiva Therapeutics specializes in advanced cancer treatment strategies. The company raised USD 35 mn in Series A funding on December 3, 2018, led by Panacea Venture, with participation from Efung Capital and Virtus Inspire Ventures. This funding round is the only known deal to date.Tactiva Therapeutics specializes in innovative cancer immunotherapy, focusing on the development of advanced adoptive cell therapy (ACT) strategies. The company’s primary product offerings involve a dual T cell receptor (TCR) platform that utilizes both CD4 and CD8 T cells reprogrammed to recognize and attack cancer cells. This approach enhances the anti-tumor efficacy by leveraging the synergistic effects of these two T cell types, potentially leading to sustained tumor control and durable remission for patients. Tactiva’s therapies aim to address a range of solid tumors and are tailored for patients undergoing cancer treatment, including those with advanced-stage cancers. The geographical markets for these products primarily include regions in North America and Europe, where the need for innovative cancer treatment options is significant.The revenue structure of Tactiva Therapeutics is based on the provision of advanced cancer immunotherapy solutions through direct partnerships and collaborations with healthcare institutions and oncology centers. Transactions occur through contracts for the application of their T cell therapy products in clinical settings, potentially involving one-time fees or ongoing treatment agreements. The company's flagship offerings, centered around its engineered T cells bearing proprietary TCRs, may be integrated into broader oncology treatment regimens. This model supports a B2B approach, where healthcare providers implement Tactiva’s therapies as part of their cancer treatment protocols, contributing to the firm's revenue stream. Specific pricing plans for these therapies have not been disclosed.Following the recent Series A funding of USD 35 mn, Tactiva Therapeutics plans to enhance its product line by developing new therapies aimed at diverse solid tumors, although specific product launch dates have not been disclosed. The company also intends to expand its presence in North America and Europe, focusing on establishing partnerships with additional healthcare providers by late 2023. The funding will support the research and development of their advanced therapies and facilitate the expansion into these targeted geographic regions.

## Funding rounds

- Series A, Dec 3, 2018, $35M — Efung Capital, Virtus Inspire Ventures, Panacea Venture

## Investors

- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A
- Virtus Inspire Ventures (https://capitalatlas.ai/funds/virtus-inspire-ventures) — Series A
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Series A